JP2001515857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515857A5 JP2001515857A5 JP2000510431A JP2000510431A JP2001515857A5 JP 2001515857 A5 JP2001515857 A5 JP 2001515857A5 JP 2000510431 A JP2000510431 A JP 2000510431A JP 2000510431 A JP2000510431 A JP 2000510431A JP 2001515857 A5 JP2001515857 A5 JP 2001515857A5
- Authority
- JP
- Japan
- Prior art keywords
- scintillant
- analyte
- expression
- sphingosine
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 description 10
- 239000012491 analyte Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 108010035597 sphingosine kinase Proteins 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU9002 | 1996-03-29 | ||
| AUPO9002A AUPO900297A0 (en) | 1997-09-08 | 1997-09-08 | A method of modulating cellular activity |
| PCT/AU1998/000730 WO1999012533A1 (en) | 1997-09-08 | 1998-09-08 | A method of modulating cellular activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001515857A JP2001515857A (ja) | 2001-09-25 |
| JP2001515857A5 true JP2001515857A5 (enExample) | 2006-01-05 |
| JP4570246B2 JP4570246B2 (ja) | 2010-10-27 |
Family
ID=3803288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000510431A Expired - Lifetime JP4570246B2 (ja) | 1997-09-08 | 1998-09-08 | 細胞活性を調節する方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1011654A4 (enExample) |
| JP (1) | JP4570246B2 (enExample) |
| AU (2) | AUPO900297A0 (enExample) |
| CA (1) | CA2302838C (enExample) |
| WO (1) | WO1999012533A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000070028A1 (en) | 1999-05-13 | 2000-11-23 | Johnson & Johnson Research Pty. Limited | Sphingosine kinase enzyme |
| AUPQ744700A0 (en) * | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
| EP1195604A1 (en) * | 2000-09-29 | 2002-04-10 | Warner-Lambert Company | Methods and compositions for screening modulators of lipid kinases |
| US6610534B2 (en) * | 2000-10-05 | 2003-08-26 | Novartis Ag | Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| US20050100547A1 (en) * | 2001-06-07 | 2005-05-12 | Pu Xia Etal | Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity |
| JP2005526809A (ja) * | 2002-03-28 | 2005-09-08 | メドベット サイエンス ピーティーワイ． リミティッド | 細胞活性を調節する方法 |
| EP1558736A4 (en) * | 2002-10-14 | 2006-05-10 | Medvet Science Pty Ltd | METHOD FOR MODULATING THE ACTIVITY OF AN EPITHELIAL CELL USING MODULATION OF FUNCTIONAL LEVELS OF SPHINGOSINE KINASE |
| EP1481680A1 (en) * | 2003-05-30 | 2004-12-01 | Aventis Pharma Deutschland GmbH | Use of S1P |
| MXPA06014888A (es) * | 2004-06-15 | 2007-03-21 | Medvet Science Pty Ltd | Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa. |
| AU2005253643B2 (en) * | 2004-06-15 | 2011-12-01 | Medvet Science Pty. Ltd. | Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants |
| EP1845971A4 (en) * | 2005-01-21 | 2009-12-30 | Medvet Science Pty Ltd | METHOD OF TREATING CELLULAR DAMAGE |
| WO2012015758A2 (en) | 2010-07-30 | 2012-02-02 | Saint Louis University | Methods of treating pain |
| WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766111A (en) * | 1985-10-31 | 1988-08-23 | Trustees Of Boston University | Lipids with plasmin inhibitory properties |
| ATE133423T1 (de) * | 1987-05-20 | 1996-02-15 | Rogosin Inst | Rekonstituierte hdl-teilchen und ihre verwendung |
| US5190876A (en) * | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
| CA2007507C (en) * | 1989-02-03 | 1998-05-19 | Yasuyuki Igarashi | Sphingosine and n-methyl-sphingosine as inhibitor of cell growth |
| US5466716A (en) * | 1990-12-31 | 1995-11-14 | The Biomembrane Institute | Liposomal trimethylsphingosine |
| CA2165982A1 (en) * | 1993-07-23 | 1995-02-02 | Fuqiang Ruan | N,n,n-trimethylsphingosine derivatives |
| EP0801568B1 (en) * | 1994-12-29 | 2002-07-17 | The Regents of the University of California | Compounds for inhibition of ceramide-mediated signal transduction |
| US5677189A (en) * | 1995-06-29 | 1997-10-14 | Oncomembrane, Inc. | Method for quantifying sphingosine and for diagnosing platelet activation |
| JPH09176083A (ja) * | 1995-12-28 | 1997-07-08 | Sankyo Co Ltd | 新規化合物ｆ−１２５０９ａ |
-
1997
- 1997-09-08 AU AUPO9002A patent/AUPO900297A0/en not_active Abandoned
-
1998
- 1998-09-08 JP JP2000510431A patent/JP4570246B2/ja not_active Expired - Lifetime
- 1998-09-08 AU AU89658/98A patent/AU757358B2/en not_active Expired
- 1998-09-08 CA CA2302838A patent/CA2302838C/en not_active Expired - Lifetime
- 1998-09-08 EP EP98941157A patent/EP1011654A4/en not_active Withdrawn
- 1998-09-08 WO PCT/AU1998/000730 patent/WO1999012533A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001515857A5 (enExample) | ||
| Wilting et al. | The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis. | |
| Wojtaszewski et al. | Wortmannin inhibits both insulin-and contraction-stimulated glucose uptake and transport in rat skeletal muscle | |
| Echizen et al. | Clinical pharmacokinetics of verapamil, nifedipine and diltiazem | |
| Calapai et al. | Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation | |
| DE69535665D1 (de) | Konjugate enthaltend ein antitumorales mittel und deren verwendung | |
| CA2332007A1 (en) | Adenosine a3 receptor modulators | |
| Labbé et al. | Clinical pharmacokinetics of mexiletine | |
| DE50014571D1 (de) | Träger-pharmaka-konjugate | |
| Gilbert et al. | Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer | |
| Alvarez et al. | Role of EETs in regulation of endothelial permeability in rat lung | |
| Pernot et al. | d-Serine diffusion through the blood–brain barrier: Effect on d-serine compartmentalization and storage | |
| JP2003507421A5 (enExample) | ||
| CA2166383A1 (en) | Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology | |
| ES2201644T3 (es) | Composicion farmaceutica a base de estrogeno y de progesterona. | |
| Peterson et al. | Cationic neutrophil proteins increase transendothelial albumin movement | |
| FI972287A0 (fi) | Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten. | |
| NO20010021D0 (no) | Trifunksjonelt reagens for konjugering til et biomolekyl | |
| FI973118A0 (fi) | Lymfotoksiini-alfa/beta-komplekseja ja antilymfotoksiini-beta-reseptorivasta-aineita kasvaimenvastaisina aineina | |
| Labrecque et al. | Rhythms and pharmacokinetics | |
| CA2302838A1 (en) | Modulation of the sphingosine kinase signalling pathway | |
| EP1407784A4 (en) | ANTITUMOR AGENTS | |
| Beasley | COX-2 and cytosolic PLA2mediate IL-1β-induced cAMP production in human vascular smooth muscle cells | |
| Banday et al. | Insulin treatment enhances AT1 receptor function in OK cells | |
| Tsutsumi et al. | Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid |